According to the website of the State Drug Administration, recently, the State Drug Administration approved the listing registration application of Yinqiao Qingre tablets. Jiangsu Kangyuan Pharmaceutical Co., Ltd. is the holder of the marketing license of this variety of drugs.
This product is an innovative traditional Chinese medicine developed on the basis of clinical experience. A multicenter, randomized, double-blind, placebo / positive drug parallel control clinical trial has been carried out. The results show that it can be used for the treatment of exogenous wind heat common cold.
The listing of the new traditional Chinese medicine provides a new treatment option for patients with common cold.
|